Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

@article{Astrup2009EffectsOL,
  title={Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study},
  author={A. Astrup and S. R{\"o}ssner and L. Gaal and A. Rissanen and L. Niskanen and Mazin Al Hakim and J. Madsen and M. Rasmussen and M. Lean},
  journal={The Lancet},
  year={2009},
  volume={374},
  pages={1606-1616}
}
BACKGROUND The frequency of obesity has risen dramatically in recent years but only few safe and effective drugs are currently available. [...] Key MethodWe did a double-blind, placebo-controlled 20-week trial, with open-label orlistat comparator in 19 sites in Europe.Expand

Paper Mentions

Interventional Clinical Trial
Diabetes is the second leading cause of end stage renal disease in France (22% in the 2016 REIN register). In hemodialysis, its prevalence is higher, between 30-40% depending on the… Expand
ConditionsDiabetes Mellitus, Type 2, Hemodialysis, Obese
InterventionDrug
Interventional Clinical Trial
To further understand the tolerability of glucagon.  
ConditionsObesity
InterventionDrug
Interventional Clinical Trial
The main purpose of this study is to examine the effect of prolonged (72 hour) administration of glucagon compared to placebo on energy expenditure in healthy, non-diabetic, obese… Expand
ConditionsObesity
InterventionDrug
Interventional Clinical Trial
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk… Expand
ConditionsCardiovascular Diseases, Fat Disorder, Obesity, Visceral
InterventionDrug
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
TLDR
3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control in patients with type 2 diabetes and prediabetes. Expand
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
TLDR
Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes in this trial, with the limitation that withdrawn individuals were not followed up after discontinuation. Expand
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
TLDR
Transient nausea and vomiting on treatment with liraglutide 3.0 mg was associated with greater weight loss, although symptoms appeared tolerable and did not attenuate quality-of-life improvements. Expand
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
TLDR
This randomized, double-blind, placebo-controlled, parallel-group trial with 12-week observational off-drug follow-up period to investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and type 2 diabetes. Expand
Multicenter, placebo-controlled trial of lorcaserin for weight management.
TLDR
In conjunction with behavioral modification, lorcaserin was associated with significant weight loss and improved maintenance of weight loss, as compared with placebo. Expand
Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center
TLDR
L treatment of OO in a real life setting yielded results comparable to those reported by the major RCCTs, and a linear correlation between early and final weight loss was found. Expand
Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
TLDR
Liraglutide 3.0 mg significantly decreased body weight in obese patients treated with antipsychotics without altering the status of psychiatric diseases. Expand
Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
TLDR
The addition of liraglutide to calorie restriction significantly augmented weight loss and improved insulin resistance, systolic blood pressure, glucose, and triglyceride concentration in this population at high risk for development of T2DM and CVD. Expand
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
TLDR
The efficacy and safety of the GLP-1 receptor agonist liraglutide as an add-on therapy to insulin for overweight adult patients with type 1 diabetes and its use in this study is registered with ClinicalTrials.gov, number NCT01612468. Expand
A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
TLDR
While the intention-to-treat analysis did not show effects of liraglutide on ectopic fat and HbA1c, per-protocol analysis showed that liragsolutide decreases visceral adipose tissue volume, which was associated with improved glycaemic control in South Asians. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes
TLDR
In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin. Expand
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
TLDR
Liraglutide once a day provided significantly greater improvements in glycaemic control than did exenatide twice a day, and was generally better tolerated, suggesting that liragLutide might be a treatment option for type 2 diabetes, especially when weight loss and risk of hypoglycaemia are major considerations. Expand
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
TLDR
Eight weeks of 0.6-mg liraglutide treatment significantly improved glycemic control without increasing weight in subjects with type 2 diabetes compared with those on placebo. Expand
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
TLDR
Liraglutide is safe and effective as initial pharmacological therapy for type 2 diabetes mellitus and leads to greater reductions in HbA(1c), weight, hypoglycaemia, and blood pressure than does glimepiride. Expand
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
TLDR
A once-daily dose of liraglutide provides efficacious glycemic control and is not associated with weight gain, and the risk of hypoglycemia is negligible. Expand
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
TLDR
As new drugs are developed, it is suggested that the assessment processes should include both surrogate endpoints and clinical outcomes, so that patients and their physicians can be confident that the putative benefits of such drugs outweigh their risks and costs. Expand
Meta-Analysis: Pharmacologic Treatment of Obesity
TLDR
This review of 79 clinical trials involving diet plus the obesity drugs sibutramine, orlistat, fluoxetine, sertraline, bupropion, topiramate, or zonisamide shows that these medications can lead to modest weight reductions of approximately 5 kg or less at 1 year. Expand
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
TLDR
Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects. Expand
Liraglutide Effect and Action in Diabetes (LEAD™) trial
  • S. Madsbad
  • Medicine
  • Expert review of endocrinology & metabolism
  • 2009
Liraglutide is the first human glucagon-like peptide-1 receptor analog, based on the structure of native glucagon-like peptide-1 with pharmacokinetic properties suitable for once-daily dosing. In theExpand
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
TLDR
The findings suggest that liraglutide, when used to regulate blood glucose levels in patients with Type 2 diabetes, improves certain biomarkers associated with increased cardiovascular risk. Expand
...
1
2
3
4
5
...